Harrow (HROW) Deferred Taxes (2017 - 2024)

Harrow (HROW) posted quarterly Deferred Taxes of $20000.0 for Q3 2024, up 106.94% quarter-over-quarter from -$288000.0 in Q1 2023.

Harrow (HROW) Deferred Taxes (2017 - 2024) Analysis & Trends

Harrow's Deferred Taxes history runs 3 years deep, the most recent figure standing at $20000.0 for Q3 2024.

In Q3 2024, Deferred Taxes changed N/A year-over-year to $20000.0; the TTM figure through Sep 2024 stood at -$1.1 million (changed N/A YoY), while the FY2018 annual figure was $3.3 million, up 452.3% from the prior year.
Deferred Taxes for Q3 2024 stood at $20000.0, up from -$288000.0 in the prior quarter.
The five-year high for Deferred Taxes was $20000.0 in Q3 2024, with the low at -$288000.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Haleon	44.34 Bn	43.38 Bn	-	-
2	Teva Pharmaceutical Industries	43.87 Bn	40.22 Bn	2.15 Bn	25.00 Mn
3	Zoetis	32.46 Bn	30.78 Bn	1.05 Bn	-33.00 Mn
4	Takeda Pharmaceutical	28.62 Bn	22.82 Bn	5.10 Bn	-
5	United Therapeutics	22.19 Bn	19.53 Bn	683.80 Mn	25.70 Mn
6	Viatris	18.97 Bn	18.08 Bn	1.46 Bn	-124.50 Mn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	-25.30 Mn
8	Elanco Animal Health	11.94 Bn	11.41 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.15 Bn	9.98 Bn	-	-
10	Harrow	1.56 Bn	1.48 Bn	50.36 Mn	-

Download Data